Investigation of White Blood Cells to Support the Development of Engineered Regulatory T Cell (Treg) Therapies
| Registry | NCT04838171 |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Enrollment | 10 (Estimated) |
| Sponsor | Quell Therapeutics Limited (Industry) |
| Conditions | Autoimmune Diseases, Inflammation, Rejection; Transplant, Liver |
| Interventions | White blood cell and blood collection (Other) |
| Dates | start 2021-03-24, primary completion 2029-12-31 (estimated), completion 2030-01-01 (estimated), first posted 2021-04-08, last updated 2026-01-21 |
| Locations | 1 site in United Kingdom |
Related Papers Related Patents Related Grants Related Experts
All trials for Autoimmune Diseases All trials for Inflammation All trials of White blood cell and blood collection
The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Specimen collection to support development of engineering Treg | Other: White blood cell and blood collection |
Sex: All, accepts healthy volunteers
No additional inclusion/ exclusion criteria will be applied by Quell other than those specified by the consenting institutions.
| Facility | City | Country | Status |
|---|---|---|---|
| Quell Investigator Site 01 | London | United Kingdom | Recruiting |